Audit: QRS - Hibiscus for Health & Longevity
Audit conducted on 03/08/2026 02:05 using AI4L + evidence-mcp / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 86 |
| Failed | 0 |
| N/A | 5 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol, timing, benefit/risk, monitoring, and at-a-glance content traces to ER content. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Conflicted/speculative framing preserved (e.g., speculative tiers, “conflicted lipid effect”). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain avoidance/threshold force. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. | 🟢 | Gates derive from ER “Key Interactions & Contraindications”; benefits/risks from their ER sections. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | QRS carries no citations, expert names, or NCT/brand identifiers. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Objective, data-driven tone consistent with ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Meets tone requirement. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence, not prescriptions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Disclaimer present; no directive advice. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Content is presented, not recommended. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain-language phrasing throughout. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact cards, gates, and table. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No “you”/”your”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing targets proactive adults. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol/monitoring assume willingness to act. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not a general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighting reflects proactive-adult lens. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | No “anti-aging” usage. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | Formal terminology; beverage terms are appropriate. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: card/section headings, gate headings, tier labels, Monitoring table column headers. | 🟢 | All fixed headings present and unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the QRS. | 🟢 | Full set of named spans present. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Untouched spans intact. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. | 🟢 | No ER source section is empty; no empty-state phrasing required. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Tier and marker labels match ER. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names and tier labels match ER. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). | 🟢 | No emoji indicators; “⚠️ Conflicted” markers stripped. |
| 4.5 | The QRS is designed to render on one A4 page. | 🟢 | Content condensed to single-page budget. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Comment opens at line 2, immediately after doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. | 🟢 | Delimited at lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless required. | 🟢 | Only “duration” quoted (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]”. | 🟢 | er_filename: hibiscus_2026-0803-0116_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”. | 🟢 | qrs_prompt_version: 26.7.02. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”. | 🟢 | qrs_creation_date: 2026-0803-0116. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”. | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus”. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”. | 🟢 | qrs_creator_ai_fullname: Opus 4.8. |
| 5.11 | The full name of the AI consists of the nickname and the model version number and no additional qualifier. | 🟢 | “Opus 4.8”. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]”. | 🟢 | qrs_filename: hibiscus_2026-0803-0116_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless required. | 🟢 | Values clean and consistent. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] followed by “ - Quick Reference Sheet”, HTML-entity-encoded as needed. | 🟢 | “Hibiscus for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic], with HTML entities encoded as needed. | 🟢 | “Hibiscus for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]. | 🟢 | “08/03/2026”. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname]. | 🟢 | “Opus 4.8”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Only standard subline present. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section. |
🟢 | Condenses the ER Conclusion. |
| 7.2 | [at_a_glance] is no longer than 60 words. | 🟢 | 53 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each claim traces to the Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge; uses plain-language terms instead. | 🟢 | Plain-language only; no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values). | 🟢 | No trial citations. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results. | 🟢 | No numeric effect sizes. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section. |
🟢 | Populations drawn from that ER section. |
| 8.2 | [stop_items] represent the Contraindications from the ER. | 🟢 | Pregnancy/lactation, low BP, surgery, liver disease. |
| 8.3 | Individual [stop_items] are formatted as <li></li>. | 🟢 | Each item is an <li>. |
| 8.4 | Items are as concise as possible; no trailing explanations or content after em/en/hyphen dash. | 🟢 | No trailing dash clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved, kept concise. | 🟢 | “systolic below ~110 mmHg”, “stop ≥2 weeks before” preserved. |
| 8.6 | When the ER uses ranking notation inside parens that depends on an explanatory phrase, normalize to a plain comma-separated list. | 🟢 | ER uses no ranking notation here; nothing to normalize. |
| 8.7 | If no [stop_items] are present the section is left empty. | N/A | Contraindications are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section. |
🟢 | Interactions drawn from that ER section. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any already listed as Contraindications. | 🟢 | Drug/supplement/iron interactions; no population overlap. |
| 9.3 | Individual [caution_items] are formatted as <li></li>. | 🟢 | Each item is an <li>. |
| 9.4 | Items are as concise as possible; no trailing explanations or content after em/en/hyphen dash. | 🟢 | No trailing dash clauses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, thresholds, staging — ARE preserved, kept concise. | 🟢 | Example drug lists preserved in parens. |
| 9.6 | When the ER uses ranking notation inside parens that depends on an explanatory phrase, normalize to a plain comma-separated list. | 🟢 | ER uses no ranking notation here; nothing to normalize. |
| 9.7 | If no [caution_items] are present the section is left empty. | N/A | Key Interactions are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section. |
🟢 | Derived from ER Therapeutic Protocol. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section. |
🟢 | Standard tea, standardized extract, timing. |
| 10.3 | If less than three distinct actionable implementation aspects are mentioned, the unused sets are left empty and made invisible. | N/A | Three distinct aspects are present. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three action cells populated. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER. | 🟢 | The two distinct aspects in the ER (BP 2–6 weeks; single serving 1–2 h) are covered; third unused. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit. | 🟢 | Blood pressure (high) first, then acute single serving. |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned, the unused sets are left empty and made invisible. | 🟢 | time_3 empty and display:none. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Both used cells populated from ER. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel. |
N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section. |
🟢 | Tiers map to ER benefit tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]. | 🟢 | All four present. |
| 12.3 | Items are as concise as possible; no explanations, effect sizes, qualifiers, attributions, citations, study details, or mechanisms. | 🟢 | Bare benefit names only. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “⚠️ Conflicted” qualifier stripped from Blood Lipids. |
| 12.5 | If no items of a specific sub-section are present the respective is set to display=none. | N/A | All four tiers contain items. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section. |
🟢 | Tiers map to ER risk tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]. | 🟢 | All four present. |
| 13.3 | Items are as concise as possible; no explanations, effect sizes, qualifiers, attributions, citations, study details, or mechanisms. | 🟢 | Bare risk names only. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “⚠️ Conflicted” stripped from liver-enzyme item. |
| 13.5 | If no items of a specific sub-section are present the respective is set to display=none. | 🟢 | risks_high has no items and is set to display:none. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section. |
🟢 | Table derived from ER Monitoring Protocol. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed. |
🟢 | All 8 biomarkers present with targets. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. |
🟢 | Cadence matches ER text. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section. |
🟢 | Qualitative markers from ER Monitoring Protocol. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed. |
🟢 | Energy/lightheadedness, sleep, digestion, well-being. |
Issues 03/08/2026 02:05
Pass rate 100.00%. No issues found.